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Isolation and characterization of a human colon
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Resistance to doxorubicin (DX) frequently emerges
in patients, limiting its use in repeated courses of
treatment (Curt et al., 1984; Goldie & Coldman,
1984). Several authors (for review, see Kaye &
Merry, 1985) have demonstrated that one
mechanism of resistance to DX involves impaired
accumulation and retention of the drug, and that
DX-resistant cells are also resistant to compounds
having different chemical structures and modes of
action.
This has been reported in vivo in murine tumours
and in vitro in established cell lines from animal
and human sources. In cell lines isolated from
patients (Shoemaker, 1983; Merry et al., 1986;
Louie et al., 1986) multi-drug resistance has been
reported, whereas reduced drug accumulation has
not been observed. Another characteristic of DX-
resistance, possibly related to reduced drug
accumulation, is enhanced production of a
membrane glycoprotein with a molecular weight
- 170,000 daltons. This has been reported in some
resistant cell lines (Kartner et al., 1985; Bhalla et
al., 1985; Roninson et al., 1984). Gene
amplification is at the origin of this overproduction,
as already observed in cells with other resistance
mechanisms (Starks & Wahl, 1983).
We selected a human colon adenocarcinoma cell
line (LoVo) isolated from a metastatic nodule for
studying DX-resistance; its morphology and
biochemical characteristics have been fully
described (Drewinko et al., 1976, 1984).
A DX-resistant subline (LoVo/DX), about 25-30
times more resistant to DX than LoVo, was
obtained in vitro after 5-6 treatments with DX. It
presents the characteristics we have summarized
viz., reduced accumulation of DX, and cross-
resistance to different antitumour substances. A
protein which is overexpressed has also been
observed (M. Ciomei, unpublished).
We also report here the cytotoxic activity and
intracellular drug accumulation of two
anthracycline analogues bearing an iodine atom in
position 4 of the aminosugar.
LoVo and LoVo/DX were cultured at 37°C in
Ham's F12 medium supplemented with 20% foetal
calf serum, 1% of a 200mM glutamine solution,
100Um-1 penicillin, 100 jg ml-1 streptomycin and
1% of a BME vitamin solution 1OOX. Cells were
passaged every 3-4 days and maintained at 37C in
an atmosphere of 5% CO2.
LoVo/Dx was obtained as follows: exponentially
growing cultures were treated with 00 ngml-1 DX;
every 2-3 weeks the medium was substituted with
fresh medium containing 100 ngml-1 DX. After 5-
6 courses of treatment, cells were harvested with
0.25% trypsin and cloned in plastic wells in the
presence of the same amount of drug. LoVo/DX is
derived from a single-cell colony and was
continuously maintained in 100ngml-1 DX.
The experiments described were performed after
30 passages in drug-containing medium. Doubling
time was determined by seeding LoVo and
LoVo/DX at concentrations of 2 x 104 and 4 x 104
cells/dish in 36mm plastic dishes (2ml/dish). Every
24h two replicate samples were harvested with
0.25% trypsin and resuspended in 2ml growth
medium: Cell number was determined with a
Coulter Counter (Mod. ZM). Plating efficiency was
measured by plating cell concentrations ranging
from 100 to 1500 cells/dish; colonies with .50
cells/colony were counted under an inverted
microscope after 8-10 days.
Clonogenic assay A single-cell plating technique
(Howell et al., 1984; Miyamoto et al., 1984) was
employed to assess cytotoxicity. Exponentially
growing cultures were harvested with 0.25% trypsin
and resuspended in growth medium; 400
cells/plastic dish (36mm) were seeded 24h before
treatment to permit the cells to adhere to the plastic
surface. Cells were exposed to the drugs by
replacing the growth medium with drug-containing
medium; exposure was 1 or 24h at 37°C, then
medium was withdrawn, attached cells were rinsed
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once with saline, and fresh growth medium was
added. Colony number was determined after 8-10
days incubation at 37°C. The 50% inhibiting dose
(ID50) was calculated from dose-response curves.
The resistance index (RI) is the ratio between ID50
values on LoVo/DX vs. LoVo.
Intracellular drug accumulation Cells were seeded
at the concentration of 1.2 x 106 cells/dish (60mm,
4ml) and incubated at 37°C for 24h before
treatment; for drug exposure, growth medium was
withdrawn and replaced with medium containing
2.5 ugml-1 of DX, daunorubicin (DNR), 4'-deoxy-
4'-I-doxorubicin (4'-I-DX) and 4'-deoxy-4'-I-dauno-
rubicin (4'-I-DNR) (Figure 1). Exposure was for
15, 30, and 60min at 37°C; then medium was
withdrawn, and cells were quickly washed twice
with ice cold saline and harvested with a few drops
of 0.25% trypsin at room temperature. Detached
cells were suspended in 3 ml ice cold saline,
collected by low-speed centrifugation at 4°C and
resuspended in ml of a 1:1 mixture of ethanol:
0.3NHCl for extraction of the drugs. Intracellular
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Figure 1 Structures of anthracyclines.
drug content was determined by fluorescence
spectrophotometry (excitation and emission
wavelengths respectively 479 and 593nm) and is
reported as ug drug 10-6 cells.
Each sample was run in triplicate. Cell number
was determined with a Coulter Counter on an
aliquot of the cell suspension before centrifugation.
Drugs The anthracyclines evaluated, DX, 4'-I-DX,
DNR,4'-I-DNR were from Farmitalia C. Erba,
Milan, Italy. Other antitumour drugs were:
mitomycin C (Kyowa Hakko, Tokyo, Japan),
vincristine suplhate (trade name 'Oncovin', Eli
Lilly, Indianapolis, USA), aclacinomycin A (NSC
208734, from NCI), VP-16-213 (trade name
'Vepesid', Bristol Myers Pharmaceuticals, Slough,
UK), actinomycin D (Sigma Chemical Co., St.
Louis, USA) and arabinosylcytosine (Ara C, Sigma
Chemical Co., St. Louis, USA). Compounds were
dissolved in sterile water and stored at -20°C in
0.2ml stocks at the concentration of 0.1mgml-1.
All subsequent dilutions were made in growth
medium immediately before treatment.
Characteristics of LoVo/DX The doubling time of
LoVo/DX and LoVo was 24h with a lag in
resuming exponential phase of 24h for LoVo and
40h for LoVo/DX. Plating efficiency was 50%
(s.d. + 12)forLoVo, andslightlyless -38% (s.d. +8.4)
- for LoVo/DX.
Cytotoxicity and intracellular content of
anthracyclines The cytotoxicity of DX, 4'-I-DX,
DNR and 4'-I-DNR was measured on LoVo and
LoVo/DX after 60min exposure (Table I).
LoVo/DX were resistant to DX and DNR (RIs
26.7 and 24.8 respectively) and much less resistant
to the iododerivatives 4'-I-DX and 4'-I-DNR (RIs
4.4 and 3 respectively). These cytotoxicity values
appear to correlate, at least qualitatively, with the
intracellular content of the drugs. Figure 2 shows
the net drug content determined on LoVo and
LoVo/DX after short exposure. In both cell lines,
Table I Cytotoxic activity of DX, 4'-I-DX, DNR and 4'-I-DNR on
LoVo and LoVo/DX cells after 60min treatment.
LoVo LoVo/DX
Product ID50 (ngml-1) ID50(ngml-1) RI
Doxorubicin 243 +15 6500+707 26.7
4'-I-Doxorubicin 13+1.5 57.5+10 4.4
Daunorubicin 125+46 3100+312 24.8
4'-I-Daunorubicin 20+8 60+7 3
ID50: mean+s.d. of 3 replicate experiments and RI: resistance index.IN VITRO STUDIES ON A HUMAN DX-RESISTANT CELL LINE
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DX and DNR reached lower intracellular levels
than their iododerivatives: Drug content in
LoVo/DX was however lower for all four
compounds, more markedly for DX and DNR than
for 4'-I-DX and 4'-I-DNR.
These two iododerivatives have been reported to
be active both in vitro and in vivo on P388 murine
leukaemia resistant to DX (Geroni et al., 1983;
Barbieri et al., 1984). 4'-I-DX has been further.
evaluated and is a clinical candidate since it is
much less cardiotoxic than DX and shows good
antitumour activity (Arcamone, 1985; Barbieri et
al., unpublished).
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Cross-resistance studies The cytotoxic activity of
different antitumour drugs after 24h exposure to
graded concentrations of the compounds is shown
in Table II. LoVo/DX cells were resistant to
doxorubicin (RI, 30.4), VP-16 (RI, 25), vincristine
(RI, 22.4) and actinomycin D (RI, 7.8). Lower
resistance was observed for aclacinomycin A (RI,
2.87) and mitomycin C (RI, 3.1). No cross-
resistance was observed with Ara-C; this compound
in fact was more active on the resistant line than on
the sensitive one. This 'collateral sensitivity' of DX-
resistant cells to Ara-C has been observed in other
studies (Johnson et al., 1978; Bhalla et al., 1985).
Table H Cytotoxic activity of different antitumour compounds on LoVo
and LoVo/DX cells after 24h exposure.
LoVo LoVoIDX
Product ID50a(ngml-,) ID50 (ngml1) RI
Doxorubicin 17.5+6 533+57 30.4
VP-16 20+5 500+52 25
Vincristine 50+8.2 1120+57 22.4
Actinomycin D 28+11 220+62 7.8
Mitomycin C 20+7 62.5+17.6 3.1
Aclacinomycin A 47.6+7.3 137+12 2.87
Ara-C 150+45 45+7 0.3
"Iso: mean+s.d. of three replicate experiments and RI: resistance index.
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Conclusions As already shown on other human
and animal DX-resistant cell lines, on LoVo/DX we
observed multi-drug resistance and reduced drug
content. The method we applied determines only
the intracellular drug content and does not measure
uptake and efflux of the drug separately. However,
we observed faster drug efflux on LoVo/DX than
on the sensitive line (data not shown). In any case,
the comparison between LoVo and LoVo/DX
clearly demonstrates a lower drug content in the
resistant line.
A puzzling question is that the low intracellular
drug content does not account for the marked
differences in sensitivity observed in the resistant
line. DX-resistance is probably a multifactorial
phenomenon; in fact very recently DX-induced
DNA damage was described as being reduced in
the P388/DX line (Capranico et al., 1986) even
when DX levels were comparable. The impaired
drug accumulation is certainly a fundamental effect,
since the cross-resistance observed to unrelated
antitumour drugs would be difficult to explain by
other mechanisms. Besides, we have shown that
DX-resistance can be partially overcome with
anthracycline analogues able to enter resistant cells.
Potentially this represents important therapeutic
properties because this new class of anthracyclines
might be active on tumours which respond poorly
to DX, and could also be used in therapy following
DX or DNR treatment.
The authors wish to thank Mr A. Dadda and Mr A.
Marsiglio for excellent technical assistance.
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